belinostat + temozolomide

Belinostat + temozolomide is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action, primarily explored in oncology. Belinostat is a histone deacetylase inhibitor that induces cell-cycle arrest and apoptosis in tumor cells by promoting the accumulation of acetylated histones and other proteins, leading to preferential cytotoxicity toward malignant cells. It is approved as monotherapy for relapsed or refractory peripheral T-cell lymphoma and has been studied in combination with other agents for hematologic malignancies and solid tumors[1][5]. Temozolomide is an oral alkylating agent used mainly to treat glioblastoma multiforme and refractory anaplastic astrocytoma; it acts by methylating DNA at the O6 and N7 positions of guanine, resulting in DNA damage and tumor cell death[2]. The rationale for combining these agents lies in their complementary mechanisms—epigenetic modulation by belinostat may sensitize tumor cells to the cytotoxic effects of DNA alkylation by temozolomide. This combination remains experimental, with ongoing research evaluating its safety, tolerability, pharmacokinetics, and antitumor activity.

Brand names

Temomedac

Other names

belinostat + temozolomide